DOCSLIB.ORG

Page Numbers in Bold Type Relate to Monograph Titles Index A769

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Page Numbers in Bold Type Relate to Monograph Titles Index A769 page numbers in bold type relate to monograph titles Index A769 Index Page numbers in bold type relate to monograph titles. Pages – Vol I: i – xxviii, (Preliminaries and Introduction) 1 – 1172, (General Notices and Monographs) Pages – Vol II: xxix – xxxvi, (Preliminaries) 1173 – 2252, (General Notices and Monographs) Pages – Vol III: xxxvii – xliv, (Preliminaries) 2253 – 3794, (General Notices and Monographs) Pages – Vol IV: xlv – lii, (Preliminaries) 3795 – 3828, (General Notices) S1 – S134, (Spectra) A1 – A768, (Appendices; Supplementary Chapters) page numbers in bold type relate to monograph titles Index A771 Acetate–edetate Buffer Solution pH 5.5, Aciclovir Tablets, 2341 A A141 Aciclovir Tablets, Dispersible, 2341 Abbreviated, A519 Acetates, Reactions of, A239 Acicular, A449 Adjectives, A519 Acetazolamide, 52,S5 Acid Blue 92, A19 Anions, A519 Acetazolamide Tablets, 2336 Acid Blue 92 Solution, A19 Cations, A519 Acetic Acid, A17 Acid Blue 83, A19 Preparations, A519 Acetic Acid (6 per cent), 54 Acid Blue 93 Solution, A19 Titles of Monographs, A519 Acetic Acid (33 per cent), 55 Acid Blue 90, A19 Abbreviated Titles, Status of, 7, 1179, Acetic Acid, Anhydrous, A18 Acid Gentian Mixture, 3585 2259, 3801 Acetic Acid, Deuterated, A46 Acid Gentian Oral Solution, 3585 Abnormal Toxicity, Test for, A354 Acetic Acid, Dilute, A18 Acid Potassium Iodobismuthate About, definition of, 5, 1177, 2257, Acetic Acid, Dilute, see Acetic Acid Solution, A100 3799 (6 per cent) Acid Value, A275 Absolute Alcohol, see Ethanol Acetic Acid, Glacial, 54, A18 Acid/base Indicators, A764 Absolute Ethanol, A56 Acetic Acid in Synthetic Peptides, Acid-base titrations, A763 Absolute Ethanol R1, A56 Determination of, A267 Acidified Chloroform, A38 Absolute viscometers, A228-229 Acetic Acid VS, A130 Acidified Dichloromethane, A48 Absorbable Braided Sutures, Sterile Acetic Acid, see Acetic Acid (33 per cent) Acidified Methanol, A78 Synthetic, 3453 Acetic Anhydride, A18 Acidified Methylene Chloride, see Absorbable Monofilament Sutures, Acetic Anhydride Solution R1, A18 Acidified Dichloromethane Sterile Synthetic, 3455 Acetic Anhydride–Dioxan Solution, A18 Acid-insoluble Ash, Determination of, Absorbent Cotton, 3449 Acetic Anhydride–Sulphuric Acid A291 Absorbent Viscose Wadding, 3450 Solution, A18 Acid-washed Diatomaceous Support, Absorption spectrophotometry, infrared, Acetic Bromine Solution, A32 A47 A149 Acetone, 55, A18 Acitretin, 66 Absorption Spectrophotometry, Acetone, Deuterated, A46 Acknowledgements, xxiii Ultraviolet and Visible, A155 Acetone Solution, Buffered, A141 Acrylamide, A19 Acacia, 39, A17 Acetone-dried Ox Brain, A90 Acrylamide/bisacrylamide (29:1) Acacia Solution, A17 Acetonitrile, A18 Solution, 30 per cent, A19 Acacia, Spray-dried, 40 Acetonitrile for Chromatography, A18 Acrylamide/bisacrylamide (36.5:1) Acamprosate Calcium, 41 Acetonitrile R1, A18 Solution, 30 per cent, A19 Acarbose, 42 Acetoxyvalerenic Acid, A18 Acrylic Acid, A19 Acarbose, Chromatogram, A645 Acetyl Chloride, A18 Acteoside, A19 Accuracy, A587 Acetyl groups (O) in Polysaccharide Action and Use Statement, Status of, 16, Acebutolol Capsules, 2335 Vaccines, A398 1188, 2268, 3810 Acebutolol Hydrochloride, 44, S4, A17 Acetyl Groups, Reactions of, A239 Activated Acid Aluminium Oxide, A21 Acebutolol Tablets, 2335 Acetyl Value, Determination of, Activated Attapulgite, 196 Aceclofenac, 46 A275-287 Activated Charcoal, 454, A37 Acemetacin, 48 Acetylacetamide, A18 Activated coagulation factors, A365 Acenocoumarol, 50,S5 Acetylacetone, A18 Activated protein C chromogenic Acenocoumarol Tablets, 2336 Acetylacetone Reagent R1, A18 substrate, A370 Acesulfame Potassium, 51 4-Acetylbiphenyl, A18 Activated Zinc, A129 Acetal, A17 N-Acetyl-e-caprolactam, A18 Active Moiety, A564 Acetaldehyde, A17 Acetylcholine Chloride, 56, A18 Active Substances, 37, 1209, see also Acetaldehyde Ammonia Trimer Acetylcysteine, 57,S6 Substances for Pharmaceutical Use Trihydrate, A17 Acetylcysteine Injection, 2337 Additions, List of, xxiv Acetaldehyde Standard Solution Acetyldigoxin, 59 Additions, List of Monographs, xx (100 ppm C2H4O), A136 b-Acetyldigoxin, Chromatogram, A646 Additives, Plastic, A513 Acetaldehyde Standard Solution b-Acetyldigoxin, see Acetyldigoxin Adenine, 67, A19 (100 ppm C2H4O) R1, A136 Acetyleugenol, A18 Adenosine, 68, A19 Acetamide, A17 N-Acetylglucosamine, A18 Adenovirus Vectors for Human Use, Acetaminophen, see Paracetamol Acetyl-11-keto-b-boswellic Acid, A18 A747 Acetate Buffer pH 2.8, A141 N-Acetyl-L-cysteine, A18 Adipic Acid, 70, A19 Acetate Buffer pH 2.45, A140 N-Acetylneuraminic Acid, A19 Adrenaline, 71, A19 Acetate Buffer pH 3.4, A141 Acetylsalicylic Acid Tablets, see Aspirin Adrenaline Acid Tartrate, 72, A19 Acetate Buffer pH 3.5, A141 Tablets Adrenaline and Cocaine Intranasal Acetate Buffer pH 3.7, A141 Acetylsalicylic Acid, see Aspirin Solution, 2345 Acetate Buffer pH 4.4, A141 N-Acetyltryptophan, 61, A19 Adrenaline (Epinephrine), S6 Acetate Buffer pH 4.6, A141 N-Acetyltryptophan, see Acetyltryptophan Adrenaline Eye Drops, Acetate Buffer pH 5.0, A141 Acetyltyrosine, 63 Neutral/Epinephrine Eye Drops, Acetate Buffer pH 6.0, A141 Acetyltyrosine Ethyl Ester, A19 Neutral, 2342 Acetate Buffer Solution pH 4.4, see Acetyltyrosine Ethyl Ester, 0.2M, A19 Adrenaline Eye Drops/Epinephrine Eye Acetate Buffer pH 4.4 N-Acetyltyrosine, see Acetyltyrosine Drops, 2342 Acetate buffer solution pH 4.6, see Aciclovir, 64 Adrenaline Injection, Bupivacaine and, Acetate Buffer pH 4.6 Aciclovir Cream, 2338 2437 Acetate Buffer Solution pH 6.0, see Aciclovir Eye Ointment, 2339 Adrenaline Injection, Dilute (1 in Acetate Buffer pH 6.0 Aciclovir Intravenous Infusion, 2339 10,000), 2344 Acetate Buffer Solution pH 4.5, A141 Aciclovir Oral Suspension, 2340 Adrenaline Injection, Lidocaine and, Acetate Buffer Solution pH 4.7, A141 Aciclovir Sodium for Intravenous 2843 Acetate Buffer Solution pH 5.0, A141 Infusion, 2339 A772 Index Adrenaline Injection/Epinephrine Agarose for Chromatography R1, Cross- Aldehydes, Determination of, A279 Injection, 2343 linked, A20 Aldrin, A20 Adrenaline Solution/Epinephrine Agarose for Electrophoresis, A20 Aleuritic Acid, A20 Solution, 2344 Agarose/Cross-linked Polyacrylamide, Alexandrian Senna Fruit, 3721 Adrenaline Tartrate A20 Alexandrian Senna Pods, see Alexandrian Injection/Epinephrine Tartrate Agarose-DEAE for Ion Exchange Senna Fruit Injection, 2343 Chromatography, A20 Alfacalcidol, 81 Adrenaline Tartrate Agglomerate, A450 Alfadex, 82 Solution/Epinephrine Tartrate Aggregate, A450 Alfentanil Hydrochloride, 84 Solution, 2344 Agnus Castus Fruit, 3468 Alfuzosin Hydrochloride, 85 Adrenaline Tartrate, see Adrenaline Acid Agrimony, 3470 Alginate Antacid Oral Suspension, Tartrate Air, Medical, 74 Compound, 2347 Adrenalone Hydrochloride, A19 Air Permeability, Specific Surface Area Alginate Oral Suspension, Raft-forming, Adsorbed Diphtheria and Tetanus by, A433 2348 Vaccine for Adults and Adolescents, Air, Synthetic, 76 Alginate Raft-forming Oral Suspension, see Diphtheria and Tetanus Vaccine Air, Synthetic Medicinal, see Synthetic Air 2348 (Adsorbed, Reduced Antigen(s) Content) Airtight Container, A471 Alginic Acid, 87 Adsorbed Diphtheria and Tetanus Airtight container, Definition of, 27, Alimemazine, S7 Vaccine, see Diptheria and Tetanus 1199, 2279, 3822 Alimemazine Oral Solution, Paediatric, Vaccine, Adsorbed Alanine, 77, A20 2348 Adsorbed Diphtheria, Tetanus and ß-Alanine, see 3-Aminopropionic Acid Alimemazine Tablets, 2349 Pertussis (Acellular Component) Albendazole, 78 Alimemazine Tartrate, 88 Vaccine, see Diphtheria, Tetanus and Albendazole Oral Suspension, Spectrum, Alizarin S, A20 Pertussis (Acellular Component) Vaccine, A710 Alizarin S Solution, A20 (Adsorbed) Albendazole Oral Suspension with Alkaline Corallin Solution, A43 Adsorbed Diphtheria, Tetanus and Minerals, Spectrum, A710 Alkaline Eye Drops, see Hypromellose Eye Pertussis Vaccine, 3258 Albumin, Bovine, A20 Drops Adsorbed Diphtheria, Tetanus, Pertussis Albumin, Human, A20 Alkaline Gentian Mixture, 3586 (Acellular Component) and Albumin Injection, Iodinated [125I], 3378 Alkaline Gentian Oral Solution, 3586 Haemophilus Type b Conjugate Albumin Solution, 3197 Alkaline Hydroxylamine Solution, A68 Vaccine, see Diphtheria, Tetanus, Albumin Solution, Human, A20 Alkaline Hydroxylamine Solution R1, Pertussis (Acellular Component) and Albumin Solution R1, Human, A20 A68 Haemophilus Type b Conjugate Vaccine, Albumin, see Albumin Solution Alkaline Impurities, Fixed Oils, A280 (Adsorbed) Alchemilla, 3471 Alkaline Potassium Mercuri-iodide Adsorbed Diphtheria, Tetanus, Pertussis Alcohol (20 per cent), 830 Solution, A100 (Acellular Component) and Hepatitis Alcohol (25 per cent), 830 Alkaline Potassium Tetraiodomercurate B (rDNA) Vaccine, see Diphtheria, Alcohol (45 per cent), 830 Solution, A101 Tetanus, Pertussis (Acellular Component) Alcohol (50 per cent), 830 Alkaline Pyrogallol Solution, A103 and Hepatitis B (rDNA) Vaccine, Alcohol (60 per cent), 830 Alkaline Sodium Picrate Solution, A114 (Adsorbed) Alcohol (70 per cent), 830 Alkaline Tetrazolium Blue Solution, Adsorbed Diphtheria, Tetanus, Pertussis Alcohol (80 per cent), 830 A120 (Acellular Component) and Alcohol (90 per cent), 830 Alkali-washed Diatomaceous Support, Inactivated Poliomyelitis Vaccine, see Alcohol, Aldehyde-free, see Ethanol A47 Diphtheria, Tetanus, Pertussis (Acellular (96%), Aldehyde-free Alkaloids, Complete Extraction of, A290 Component) and Poliomyelitis Alcohol, see Ethanol (96%) Alkaloids, Reactions of, A239 (Inactivated) Vaccine, (Adsorbed) Alcoholic Calcium Standard Solution
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Use of Gasotransmitters for the Controlled Release of Polymer
    Journal of Controlled Release 279 (2018) 157–170 Contents lists available at ScienceDirect Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel Review article Use of gasotransmitters for the controlled release of polymer-based nitric T oxide carriers in medical applications ⁎ ⁎⁎ Chungmo Yanga,1, Soohyun Jeonga,1, Seul Kub, Kangwon Leea,c, , Min Hee Parka, a Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea b School of Medicine, Stanford University, 291 Campus Drive, Stanford, CA 94305, USA c Advanced Institutes of Convergence Technology, Gyeonggi-do 16229, Republic of Korea ARTICLE INFO ABSTRACT Keywords: Nitric Oxide (NO) is a small molecule gasotransmitter synthesized by nitric oxide synthase in almost all types of Nitric oxide mammalian cells. NO is synthesized by NO synthase by conversion of L-arginine to L-citrulline in the human Polymeric carrier body. NO then stimulates soluble guanylate cyclase, from which various physiological functions are mediated in fi Hydrogen sul de a concentration-dependent manner. High concentrations of NO induce apoptosis or antibacterial responses Carbon monoxide whereas low NO circulation leads to angiogenesis. The bidirectional effect of NO has attracted considerable Crosstalk of gasotransmitters attention, and efforts to deliver NO in a controlled manner, especially through polymeric carriers, has been the Stimuli-responsive topic of much research. This naturally produced signaling molecule has stood out as a potentially more potent therapeutic agent compared to exogenously synthesized drugs. In this review, we will focus on past efforts of using the controlled release of NO via polymer-based materials to derive specific therapeutic results.
    [Show full text]
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Current Status of Local Penile Therapy
    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
    [Show full text]
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Neonatal Intensive Care Drug Therapy Update: a Bibliography
    LWW/JPNN AS310-13 July 28, 2004 23:11 Char Count= 0 J Perinat Neonat Nurs Vol. 18, No. 3, pp. 292–306 c 2004 Lippincott Williams & Wilkins, Inc. Neonatal Intensive Care Drug Therapy Update: A Bibliography Jason Sauberan, PharmD BIBLIOGRAPHY I. Overview A. Clark RH, Bloom BT, Gerstmann DR Medications Used in Neonatal Intensive Care Units—A Descriptive Study [abstract 3047]. In: Program and abstracts of the 2004 Pediatric Academic Societies’ Annual Meeting, San Francisco, CA. B. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M. Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol. 2002 Feb;19(2):67–72. C. O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002 Nov;110(5):e52. D. Committee on Drugs. American Academy of Pediatrics. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002 Jul;110(1 Pt 1):181–3. II. Anti-infectives A. Linezolid 1. Deville JG, Adler S, Azimi PH, Jantausch BA, Morfin MR, Beltran S, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J. 2003 Sep;22(9 Suppl):S158–63. 2. Vo M, Cirincione BB, Rubino CM, Jungbluth GL. Pharmacokinetics of Linezolid in Neonates and Young Infants [abstract A-1409]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Epinephrine Versus Tramazoline to Reduce Nasal Bleeding During Nasotracheal Intubation. a Double- Blind Randomized Trial
    Epinephrine versus tramazoline to reduce nasal bleeding during nasotracheal intubation. A double- blind randomized trial Aiji Sato(Boku) ( [email protected] ) Aichi Gakuin University Yoshiki Sento Nagoya City University Yuji Kamimura Nagoya City University Eisuke Kako Nagoya City University Masahiro Okuda Aichi Gakuin University Naoko Tachi Aichi Gakuin University Yoko Okumura Aichi Gakuin University Mayumi Hashimoto Aichi Gakuin University Hiroshi Hoshijima Tohoku University Fumihito Suzuki Akita National Hospital Kazuya Sobue Nagoya City University Research Article Keywords: Nasotracheal intubation, Epinephrine, Tramazoline, Nasal bleeding Posted Date: February 10th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-148779/v1 Page 1/14 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/14 Abstract BACKGROUND Nasal bleeding is the most common complication during nasotracheal intubation (NTI). To reduce nasal bleeding, the nasal cavity is treated with vasoconstrictors (epinephrine [E] or tramazoline [T]) prior to NTI. This study aimed to determine whether E or T is more effective and safe for reducing nasal bleeding during NTI. METHODS This study was preregistered on UMIN-CTR after being approved by the IRB of the School of Dentistry at Aichi Gakuin University. Written consent was received from all the patients. Total 206 patients aged 20–70 years and classied as 1–2 on American Society of Anesthesiologists-physical status were scheduled to undergo general anesthesia with NTI. Patients with a narrowed nasal cavity observed during preoperative CT test (n = 3), patients with hypertension (n = 3), patients undergoing antithrombotic therapy, and patients who did not give consent (n = 3) were excluded from the study.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Application and Review of Pediatric Pharmacotherapy, Sample Chapter
    Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 Section 1 Neonatal intensive care “Luck is where preparation meets opportunity.” This section consists of 16 medication orders followed by corresponding patient profiles representing pharmacotherapy associated with patients admit- ted to a neonatal intensive care unit. Each patient profile is followed by multiple-choice questions pertaining to the medication order and profile infor- mation. Choose the one best-lettered response to each item. The correct answers are provided at the end of this section. The reader is encouraged to attempt all questions for each case or for the entire section prior to referring to the answers. Moreover, where appropriate, the answer key provides a thor- ough explanation of the correct response and should serve as an additional learning tool for the reader. Application and Review of Pediatric Pharmacotherapy Chapter No. 1 Dated: 29/7/2010 At Time: 16:16:4 2 | Application and Review of Pediatric Pharmacotherapy Medication orders Physician order Patient weight: 2.5 kg Aminophylline 10 mg iv load, then begin 2.5 mg iv q 12 h Obtain theophylline concentration 1 h postinfusion of loading dose Date/time: 12/01/2100 Patient name: Baby Boy Turner Physician: John Craver Patient ID: 111222 Medical profile Patient: Baby Boy Turner Patient weight: 2.5 kg Age: 1d/o Present illness: Apneic episodes Allergies: None Medical history: 33 weeks gestation, Apgar 7 and 9 Labs: pending Medication profile Questions Q1 Which of the following is an acceptable definition of apnea of prematurity? 1 o cessation of breathing for less than 20 s 2 o cessation of breathing for at least 20 s 3 o cessation of breathing for less than 20 s when accompanied by bradycardia A o 1 only B o 3 only C o 1 and 3 only Application and Review of Pediatric Pharmacotherapy Chapter No.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]